---
title: "Zepbound (tirzepatide) in chronic weight management: Safety questions"
description: "Safety questions on Zepbound (tirzepatide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: Zepbound vs Wegovy: how do the side effects compare (SURMOUNT-5)? What are the most common side effects of Zepbound? How common is nausea on Zepbound? Does Zepbound nausea go away? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Zepbound (tirzepatide) in chronic weight management: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Zepbound](https://uspl.lilly.com/zepbound/zepbound.html#pi)

Safety questions that apply to every indication of Zepbound are on [Zepbound (tirzepatide), all indications: Safety](https://www.evicenter.com/medical-information/zepbound/safety).

## Side effects

<a id="zepbound-vs-wegovy-side-effects"></a>

### Zepbound vs Wegovy: how do the side effects compare (SURMOUNT-5)?

> “Table depicting adverse reactions that occurred in ≥5% of participants in at least one of the treatment groups: Zepbound MTD (10 mg or 15 mg) (n=374) or Wegovy MTD (1.7 mg or 2.4 mg) (n=376). 43.6% of participants taking Zepbound and 44.4% of participants taking Wegovy experienced nausea. 27.0% of participants taking Zepbound and 28.5% of participants taking Wegovy experienced constipation. 23.5% of participants taking Zepbound and 23.4% of participants taking Wegovy experienced diarrhea. 15.0% of participants taking Zepbound and 21.3% of participants taking Wegovy experienced vomiting. 13.6% of participants taking Zepbound and 12.5% of participants taking Wegovy experienced COVID-19. 10.4% of participants taking Zepbound and 12.2% of participants taking Wegovy experienced fatigue. 9.9% of participants taking Zepbound and 7.7% of participants taking Wegovy experienced eructation. 8.6% of participants taking Zepbound and 0.3% of participants taking Wegovy experienced injection site reaction. 8.6% of participants taking Zepbound and 11.4% of participants taking Wegovy experienced upper respiratory tract infection. 8.3% of participants taking Zepbound and 6.1% of participants taking Wegovy experienced hair loss. 7.2% of participants taking Zepbound and 6.4% of participants taking Wegovy experienced abdominal distention. 7.2% of participants taking Zepbound and 7.2% of participants taking Wegovy experienced headache. 6.4% of participants taking Zepbound and 6.9% of participants taking Wegovy experienced abdominal pain. 6.4% of participants taking Zepbound and 4.8% of participants taking Wegovy experienced dizziness. 6.1% of participants taking Zepbound and 10.6% of participants taking Wegovy experienced gastroesophageal reflux disease. 5.9% of participants taking Zepbound and 7.4% of participants taking Wegovy experienced dyspepsia. 4.5% of participants taking Zepbound and 5.1% of participants taking Wegovy experienced decreased appetite. 4.5% of participants taking Zepbound and 6.1% of participants taking Wegovy experienced nasopharyngitis. 2.9% of participants taking Zepbound and 5.6% of participants taking Wegovy experienced sinusitis.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Table%20depicting%20adverse%20reactions%20that,participants%20taking%20Wegovy%20experienced%20sinusitis.)

On the page, select: Show description

> “The proportion of adults who discontinued the study drug due to adverse events was 6.1% for the Zepbound-treated group and 8.0% for the Wegovy-treated group.<sup>14</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=The%20proportion%20of%20adults%20who,and%208.0%25%20for%20the%20Wegovy%2Dtreated)

> “Limitations of an open-label study may be related to a bias in evaluation of the outcomes, efficacy and/or safety, and the study did not have a comparison with placebo.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Limitations%20of%20an%20open%2Dlabel%20study,have%20a%20comparison%20with%20placebo.)

Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site; the Zepbound Prescribing Information does not describe this trial.

<a id="zepbound-side-effects"></a>

### What are the most common side effects of Zepbound?

> “Table 1 shows common adverse reactions associated with the use of ZEPBOUND in the pool of two placebo-controlled trials for weight reduction (Study 1 and Study 2). These adverse reactions occurred more commonly with ZEPBOUND than with placebo and occurred in at least 2% of patients treated with ZEPBOUND.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%201%20shows%20common%20adverse,of%20patients%20treated%20with%20ZEPBOUND.)

> “Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2)
>
> a Includes diarrhea, frequent bowel movements.
>
>
>
>
> b Includes constipation, feces hard.
>
>
>
>
> c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness.
>
>
>
>
> d Includes multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction.
>
>
>
>
> e Includes asthenia, fatigue, lethargy, malaise.
>
>
>
>
> f Includes blood pressure decreased, hypotension, orthostatic hypotension.
>
>
>
>
>
> Adverse Reaction	
> Placebo
> (N=958)
> %	ZEPBOUND
> 5 mg
> (N=630)
> %	ZEPBOUND
> 10 mg
> (N=948)
> %	ZEPBOUND
> 15 mg
> (N=941)
> %
> Nausea	8	25	29	28
> Diarrheaa	8	19	21	23
> Vomiting	2	8	11	13
> Constipationb	5	17	14	11
> Abdominal Painc	5	9	9	10
> Dyspepsia	4	9	9	10
> Injection Site Reactionsd	2	6	8	8
> Fatiguee	3	5	6	7
> Hypersensitivity Reactions	3	5	5	5
> Eructation	1	4	5	5
> Hair Loss	1	5	4	5
> Gastroesophageal Reflux Disease	2	4	4	5
> Flatulence	2	3	3	4
> Abdominal Distension	2	3	3	4
> Dizziness	2	4	5	4
> Hypotensionf	0	1	1	2”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%201%3A%20Adverse%20Reactions%20%28%E2%89%A52%25,2)

> “In Study 3 and Study 4, adverse reactions were similar to those reported in the two pooled ZEPBOUND clinical trials (Study 1 and Study 2).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20Study%203%20and%20Study,%28Study%201%20and%20Study%202%29.)

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients). The clinical data page of the Zepbound HCP site presents the same pooled rates as SURMOUNT-1 and SURMOUNT-2.

<a id="zepbound-nausea"></a>

### How common is nausea on Zepbound?

> “Adverse Reaction	
> Placebo
> (N=958)
> %	ZEPBOUND
> 5 mg
> (N=630)
> %	ZEPBOUND
> 10 mg
> (N=948)
> %	ZEPBOUND
> 15 mg
> (N=941)
> %”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=hypotension%2C%20orthostatic%20hypotension.-,Adverse%20Reaction,%28N%3D941%29)

> “Nausea	8	25	29	28
> Diarrheaa	8	19	21	23
> Vomiting	2	8	11	13”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Nausea-,8,13)

> “In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5 mg 56%, 10 mg 56%, 15 mg 56%) than placebo (30%). More patients receiving ZEPBOUND 5 mg (1.9%), ZEPBOUND 10 mg (3.3%), and ZEPBOUND 15 mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20pool%20of%20Study,than%20patients%20receiving%20placebo%20%280.5%25%29.)

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).

<a id="zepbound-nausea-go-away"></a>

### Does Zepbound nausea go away?

> “The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20majority%20of%20nausea%2C%20vomiting%2C,escalation%20and%20decreased%20over%20time.)

> “The majority of reports of nausea, vomiting, and/or diarrhea occurred during the initial 60-week, open-label weight-loss period and decreased over time.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=The%20majority%20of%20reports%20of%20nausea%2C%20vomiting%2C%20and%2For%20diarrhea%20occurred%20during%20the,-initial%2060%2Dweek%2C%20open%2Dlabel)

Note: The first passage is from the pooled Study 1 and Study 2 results of the Prescribing Information. The second is from SURMOUNT-MAINTAIN on the clinical data page of the Zepbound HCP site; the Prescribing Information does not describe that trial.

<a id="zepbound-manage-gi-side-effects"></a>

### How can Zepbound nausea and stomach side effects be reduced?

> “In order to mitigate gastrointestinal side effects, patients may find it helpful to<sup>3-5</sup>:
> Eat smaller meals
>
> Suggest that they split 3 daily meals into 4 or more smaller meals
>
> Stop eating when they feel full
> Avoid fatty foods
> Try eating bland foods
> Drink plenty of water
>
> Encourage patients to eat healthy meals to ensure they meet their needs for protein, micronutrients, fiber, and fluids.
>
> *Side effects may vary and should be evaluated by the healthcare provider for appropriate management.”

Source: [ZEPBOUND: Dosage Options, Schedules & Missed Doses, captured 2026-11-12](https://zepbound.lilly.com/hcp/dosage#:~:text=In%20order%20to%20mitigate%20gastrointestinal,healthcare%20provider%20for%20appropriate%20management.)

> “Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Follow%20the%20dosage%20escalation%20below,%285.2%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

> “Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms [see Warnings and Precautions (5.2)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Inform%20patients%20of%20the%20potential,%5Bsee%20Warnings%20and%20Precautions%20%285.2%29%5D.)

Note: The eating suggestions are from the dosing page of the Zepbound HCP site, which cites published reviews of medication-related nausea and GLP-1 receptor agonist use; they do not appear in the Prescribing Information.

<a id="zepbound-stopping-for-side-effects"></a>

### How many people stop taking Zepbound because of side effects?

> “ZEPBOUND was evaluated for safety in a pool of two randomized, double-blind, placebo-controlled trials that included 2,519 adult patients with obesity or overweight treated with ZEPBOUND for up to 72 weeks and a 4-week off drug follow-up period (Study 1 and Study 2) [see Clinical Studies (14.1)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=ZEPBOUND%20was%20evaluated%20for%20safety,2%29%20%5Bsee%20Clinical%20Studies%20%2814.1%29%5D.)

> “Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5 mg, 10 mg, and 15 mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo. The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Across%20both%20trials%2C%204.8%25%2C%206.3%25%2C,due%20to%20gastrointestinal%20adverse%20reactions.)

> “More patients receiving ZEPBOUND 5 mg (1.9%), ZEPBOUND 10 mg (3.3%), and ZEPBOUND 15 mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=More%20patients%20receiving%20ZEPBOUND%205,than%20patients%20receiving%20placebo%20%280.5%25%29.)

> “In Study 3, 10% of ZEPBOUND-treated patients and 2% of placebo-treated patients discontinued drug due to adverse reactions. In Study 4, 7% of patients discontinued ZEPBOUND treatment before randomized withdrawal at Week 36 due to adverse reactions.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20Study%203%2C%2010%25%20of,36%20due%20to%20adverse%20reactions.)

<a id="zepbound-side-effects-over-time"></a>

### What are the long-term side effects of Zepbound (SURMOUNT-MAINTAIN)?

> “Table showing the adverse events that emerged during treatment and occurred in ≥5% of participants in any treatment group in SURMOUNT-MAINTAIN. Deaths occurred in <1% of participants taking Zepbound MTD (10 mg or 15 mg) (n=441) from week 0 to week 60. From week 60 to week 112, deaths occurred in 0% of patients who received Zepbound MTD (10 mg or 15 mg) (n=139), who had their dose reduced to Zepbound 5 mg (n=142), or who were switched to placebo (n=91). From week 0 to week 60, participants taking Zepbound MTD (10 mg or 15 mg) (n=441) experienced: nausea: 35%, vomiting: 17%, diarrhea: 24%, constipation: 31%, eructation: 8%, dyspepsia: 7%, gastroesophageal reflux disease: 7%, abdominal pain: 6%, abdominal distension: 5%, upper respiratory tract infection: 7%, COVID-19: 7%, influenza: 5%, sinusitis: 3%, urinary tract infection: 3%, injection site reaction: 9%, fatigue: 10%, headache: 9%, dizziness: 7%, decreased appetite: 5%, and alopecia: 9%. Participants taking Zepbound MTD (10 mg or 15 mg) (n=139) experienced from week 60 to week 112: nausea: 6%, vomiting: 6%, diarrhea: 7%, constipation: 1%, eructation: 3%, dyspepsia: 2%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 3%, upper respiratory tract infection: 1%, COVID-19: 1%, influenza: 4%, sinusitis: 5%, urinary tract infection: 5%, injection site reaction: 6%, fatigue: 1%, headache: 2%, dizziness: 1%, decreased appetite: 0%, and alopecia: 1%. Participants who had their dose reduced to Zepbound 5 mg (n=142) experienced from week 60 to week 112: nausea: 4%, vomiting: 1%, diarrhea: 5%, constipation: 4%, eructation: 1%, dyspepsia: 1%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 1%, upper respiratory tract infection: 4%, COVID-19: 3%, influenza: 1%, sinusitis: 5%, urinary tract infection: 1%, injection site reaction: 2%, fatigue: 0%, headache: 4%, dizziness: 1%, decreased appetite: 0%, and alopecia: 0%. Participants who were switched to placebo (n=91) experienced from week 60 to week 112: nausea: 2%, vomiting: 0%, diarrhea: 1%, constipation: 4%, eructation: 0%, dyspepsia: 0%, gastroesophageal reflux disease: 1%, abdominal pain: 0%, abdominal distension: 1%, upper respiratory tract infection: 2%, COVID-19: 0%, influenza: 4%, sinusitis: 0%, urinary tract infection: 0%, injection site reaction: 0%, fatigue: 0%, headache: 3%, dizziness: 0%, decreased appetite: 0%, and alopecia: 0%.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Table%20showing%20the%20adverse%20events,0%25%2C%20decreased%20appetite%3A%200%25%2C%20and%20alopecia%3A%200%25.)

On the page, select: Show description

> “<sup>a</sup>During the weight-loss period, participants initiated tirzepatide at 2.5 mg once weekly and titrated in 2.5 mg increments every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was achieved. Data obtained during the weight-maintenance period after rescue Zepbound were excluded.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=the%20weight%2Dloss%20period%2C%20participants%20initiated,period%20after%20rescue%20Zepbound%20were)

> “Randomization at week 60 required participants to tolerate at least the 10 mg dose during the weight-loss period and to achieve a ≥5% reduction in body weight.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Randomization%20at%20week%2060%20required,a%20%E2%89%A55%25%20reduction%20in%20body)

> “SURMOUNT-MAINTAIN was conducted in adults with obesity who tolerated at least tirzepatide 10 mg and achieved ≥5% bodyweight reduction during the open-label Weight-Loss Period; therefore, results may not be generalizable to all patients.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=SURMOUNT%2DMAINTAIN%20was%20conducted%20in%20adults,be%20generalizable%20to%20all%20patients.)

> “The majority of adults who discontinued Zepbound due to adverse events did so during the initial 60-week, open-label weight-loss period.<sup>18</sup>
>
> The most common adverse events occurring more frequently with Zepbound than with placebo were GI related.<sup>18</sup>
>
> The majority of reports of nausea, vomiting, and/or diarrhea occurred during the initial 60-week, open-label weight-loss period and decreased over time.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=The%20most%20common%20adverse%20events,weight%2Dloss%20period%20and%20decreased%20over)

Note: SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.

<a id="zepbound-hair-loss"></a>

### Does Zepbound cause hair loss?

> “Adverse Reaction	
> Placebo
> (N=958)
> %	ZEPBOUND
> 5 mg
> (N=630)
> %	ZEPBOUND
> 10 mg
> (N=948)
> %	ZEPBOUND
> 15 mg
> (N=941)
> %”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=hypotension%2C%20orthostatic%20hypotension.-,Adverse%20Reaction,%28N%3D941%29)

> “Hair Loss	1	5	4	5”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=5-,Hair%20Loss,5)

> “Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction. In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Hair%20loss%20adverse%20reactions%20in,treatment%20due%20to%20hair%20loss.)

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).

<a id="zepbound-heart-rate"></a>

### Does Zepbound increase heart rate?

> “In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in a mean increase in heart rate of 1 to 3 beats per minute compared to no increase in placebo-treated patients.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20pool%20of%20Study%201%20and%202%2C%20treatment,no%20increase%20in%20placebo%2Dtreated%20patients.)

> “At 72 weeks, participants in the pooled Zepbound arm had a mean pulse rate increase of 1.8 beats/minute compared to a mean baseline of 72.2 beats/minute. The placebo arm has a mean pulse rate increase of 0.1 beats/minute compared to a mean baseline of 72.9 beats/minute. Results were not adjusted for type I error.<sup>1,10</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=At%2072%20weeks%2C%20participants%20in,not%20adjusted%20for%20type%20I)

## Related pages
- [Medical information: Zepbound (tirzepatide): Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/access-and-coverage)
